Can foreign healthcare companies own hospitals in China?
Yes, foreign healthcare companies can own hospitals in China, but under strict regulatory frameworks that limit full ownership to WFOE (外商独资企业, waishang duzi qiye) models only after meeting specific investment thresholds—currently a minimum of RMB 1 billion (approx. USD 140 million) for greenfield hospitals in free trade zones. Since the first major reform in 2023–2024, the government has expanded pilot policies, but most foreign hospital ownership still requires a joint venture (JV) with a Chinese partner. As of 2025, only 8 fully foreign-owned hospitals operate nationwide, while over 350 foreign-invested hospitals exist as JVs. This FAQ answers the most critical questions for executives evaluating entry into China’s hospital sector.
Why This Matters
China’s healthcare market is the second-largest in the world, with total health expenditure exceeding RMB 7.6 trillion (USD 1.05 trillion) in 2024. Foreign hospitals bring high-end services, advanced technology, and international standards that the domestic system urgently needs, especially in tier‑1 cities. However, ownership structure directly affects control, profit repatriation, and operational flexibility. Misunderstanding the rules can lead to wasted capital, partnership disputes, or even forced divestment. For a healthcare company planning a China entry, knowing whether full ownership is possible—and under what conditions—is the first strategic decision.
Frequently Asked Questions
-
1. What legal entities can a foreign healthcare company use to own a hospital in China?
There are three main structures: a Wholly Foreign-Owned Enterprise (WFOE), a Joint Venture (JV), and a Representative Office (which cannot operate a hospital). Since 2023, WFOEs are allowed to own hospitals in selected free trade zones (FTZs) and pilot areas like Hainan, Shanghai, and Beijing. However, the WFOE must be a special purpose company registered with the National Health Commission (NHC) and meet a registered capital of at least RMB 1 billion. For most foreign investors, a JV with a Chinese hospital group remains the most common path, with the foreign party holding between 70% and 90% equity in practice, though caps vary by region.
-
2. Are there any ownership percentage limits for foreign investors in hospitals?
Yes, historically foreign ownership was capped at 70% for hospitals under the 2011–2022 catalogues. The 2024 updated Special Administrative Measures for Foreign Investment Access (2024 Edition) removed the 70% ceiling for certain FTZs and pilot sites, allowing 100% foreign ownership of general hospitals and specialized medical institutions (e.g., orthopedics, oncology). However, the measure explicitly excludes: traditional Chinese medicine hospitals, psychiatric hospitals, and blood/plasma centers. In practice, the local government approval process may still impose de facto limits. For example, in Shanghai FTZ, the city health bureau often requires a 20–30% local partner stake to ensure “public service alignment.”
-
3. What is the minimum investment required to set up a foreign-owned hospital?
For a greenfield WFOE hospital, the National Development and Reform Commission (NDRC) and Ministry of Commerce (MOFCOM) have established a minimum total investment of RMB 1 billion (USD 140 million) for projects in pilot FTZs, as per the 2023 Pilot Plan. In Hainan, where the first foreign-owned Boao Lecheng hospital was built, the threshold was RMB 500 million (USD 70 million) for specialized facilities. For Joint Ventures, no universal floor exists, but realistic capex for a 100‑bed international hospital in Shanghai starts at USD 50–80 million. Additionally, a foreign hospital must maintain a minimum registered capital of 50% of total investment for debt financing—effectively locking in at least RMB 500 million in equity.
-
4. Which regions allow 100% foreign ownership of hospitals today?
As of 2025, the following regions have explicit pilot policies for wholly foreign-owned hospitals (WFOE):
- Hainan Province (Boao Lecheng International Medical Tourism Pilot Zone) – first mover, since 2013, now fully open.
- Shanghai FTZ (including Lingang area) – since July 2023.
- Beijing FTZ (including Zhongguancun Science Park) – effective January 2024.
- Guangdong FTZ (Nansha, Qianhai, Hengqin) – pilot expanded in 2024.
- Sichuan FTZ (Chengdu) and Chongqing – limited to one project each.
Outside these zones, foreign hospitals must be joint ventures with at least 20% Chinese ownership (state-owned or private). The central government is evaluating a national rollout by 2027, but currently, only 8 foreign-owned hospitals exist across all pilot zones.
-
5. Can a foreign company own a chain of hospitals under one WFOE?
Yes, but only if the WFOE is registered as a “hospital group” (医疗集团, yiliao jituan) under the NHC and meets stricter capital requirements. The parent WFOE must have a total investment of at least RMB 3 billion (USD 420 million) and each hospital in the chain must be licensed separately. The first foreign-owned hospital chain, “United Family Healthcare” (owned by New Frontier Health Corp, a U.S.–Chinese entity) operates 7 hospitals through a JV structure. No WFOE hospital chain has been approved yet—only single-site pilots. The regulatory environment for multi‑site ownership remains uncertain; local authorities can reject applications if they deem the chain “unnecessary for public health.”
-
6. What medical services are restricted or prohibited for foreign-owned hospitals?
Foreign-owned hospitals cannot provide services in the following categories, per the 2024 Negative List:
- Traditional Chinese Medicine (TCM) inpatient treatment and acupuncture for critical conditions.
- Psychiatric hospitals and substance abuse rehabilitation.
- Blood donation, plasma collection, and stem cell banking for unrelated donors.
- Infectious disease wards (tuberculosis, HIV, etc.) – must be operated by public hospitals.
- Organ transplantation procurement (except if hospital is a recognized transplant center, which is extremely rare for foreign entities).
Additionally, all foreign hospital doctors must hold a Chinese medical license (执业医师执业证书, zhiye yishi zhiye zhengshu). Foreign physicians can apply after 5 years of experience, but the hospital must sponsor their work visa and guarantee a minimum of 60% Chinese medical staff in the first 3 years.
-
7. How long does it take to get approval for a foreign-owned hospital?
The official process involves four to six months for preliminary approval (NDRC, MOFCOM, NHC reviews) in pilot zones, but full operational licensing (including construction, fire safety, medical equipment registration) can take 18 to 24 months. For a Joint Venture hospital, approvals are faster (8–12 months) because the Chinese partner handles local compliance. The slowest step is the “hospital establishment permit” (设置医疗机构批准书, shezhi yiliao jigou pizhunshu) which requires a feasibility study, land use rights, and community health impact assessment. In 2024, only 5 foreign-owned hospital applications were approved nationwide—out of 31 submitted.
Ownership Structure Comparison Table
| Structure | Equity Cap | Min. Investment | Geography | Approval Time | Profit Repatriation |
|---|---|---|---|---|---|
| WFOE (full ownership) | 100% allowed (pilot zones) | RMB 1 billion (USD 140M) | Hainan, Shanghai, Beijing, Guangdong FTZs | 18–24 months | Unrestricted after tax |
| Joint Venture (foreign majority) | 70%–90% typical | USD 50M–100M | Anywhere (non‑restricted areas) | 8–12 months | Dividend tax: 5%–10% (subject to DTT) |
| Joint Venture (foreign minority) | <50% | USD 20M–50M | Anywhere | 6–9 months | Limited control; dividends per equity |
| Management Service Contract | 0% ownership | N/A (fee‑based) | Anywhere | 3–6 months | Service fees, subject to 25% CIT |
Common Pitfalls and Regulatory Traps
Pitfall 1: Underestimating local partnership expectations
Even where full WFOE ownership is legal, local health commissions often pressure foreign applicants to include a local partner. In 2024, two WFOE hospital projects in Guangzhou were “requested” to bring in a state-owned enterprise (SOE) to hold a 10% golden share—a veto stake in key decisions. Without a local partner, land allocation and building permits may be significantly delayed. The Chinese term for this approach is “yielding control to gain access” (以退为进, yǐ tuì wéi jìn). Factor an extra 6–12 months into your timeline if you insist on 100% ownership.
Pitfall 2: Ignoring classification of hospital type
Foreign-owned hospitals are automatically classified as “for-profit” institutions under Chinese law. This means they cannot access government subsidies, public health insurance (medical insurance, yīliáo bǎoxiǎn) reimbursement, or land discounts reserved for public or “non-profit” hospitals. Many foreign investors assume they can operate as “community-serving” to get tax benefits, but that classification is only available to Chinese-owned non-profits. The result: profit margins are thinner—average net profit for foreign hospitals is 8–12% compared to 15–20% for domestic private chains.
Pitfall 3: Misunderstanding medical insurance (医保, yībǎo) billing
Foreign-owned hospitals must apply separately to be designated as a “medical insurance designated institution” (医保定点医疗机构, yībǎo dìngdiǎn yīliáo jīgòu). Without this, patients cannot use their government insurance to pay for services, drastically limiting patient volume. However, the approval process is opaque and often denied to WFOE hospitals (only 2 out of 8 current WFOE hospitals have yībǎo coverage). Many foreign hospitals opt to accept commercial international insurance only, but that caps the patient base at 3% of the population. A wise strategy is to partner with a domestic hospital to share yībǎo billing rights.
Pitfall 4: Staffing ratios and foreign doctor licensing
China requires at least 60% of medical professionals in any foreign‑invested hospital to be Chinese nationals with local licenses. Foreign doctors can only be employed if they hold a valid Chinese medical license (examined in Mandarin). The pass rate for foreign candidates is below 15% in the first attempt. Plan for a multi‑year onboarding pipeline. Also, the “chief physician” of the hospital (院长, yuànzhǎng) must be a Chinese citizen with at least 15 years of clinical experience—a non‑negotiable rule that effectively gives local authorities oversight of medical governance.
Where to Go From Here
Based on your company’s risk appetite and capital readiness, here are three decision‑path recommendations:
- Full Ownership in a Pilot Zone (High Capital, High Control)
If you have a minimum of USD 140 million to deploy and are comfortable with a 2‑year regulatory timeline, apply for a WFOE hospital in Hainan or Shanghai FTZ. This path yields maximum operational independence but requires heavy legal and political navigation. Engage a China‑based healthcare regulatory consultant (not a general business lawyer) from the outset. - Joint Venture with a Chinese Hospital Group (Moderate Capital, Shared Risk)
For companies with USD 50–100 million and a desire to enter quickly, a JV with a top‑tier Chinese private hospital chain (e.g., Huayi Medical Group, Fosun Healthcare) offers a proven route. The foreign partner can typically secure 70–90% equity while leveraging the Chinese partner’s land, insurance access, and regulatory relationships. Expect to pay a technology licensing or brand fee of 3–5% of annual revenue to the partner. - Management or Service Contract (Low Capital, Test the Water)
If you are uncertain about ownership or have less than USD 20 million to commit, consider a Hospital Management Agreement (HMA) where you provide operational expertise, IT systems, or specialized training to an existing Chinese hospital. This structure avoids all ownership hurdles and can generate USD 2–5 million in annual fees. Use this path to gather market data and build relationships before transitioning to a JV or WFOE.
No matter which path you choose, we recommend a 90‑day pre‑feasibility study with a local law firm and a health industry advisor. The regulatory landscape is shifting quickly—the National Healthcare Security Administration and the NDRC may announce further liberalization for the 2026–2030 Five‑Year Plan. Staying early in the queue in a pilot zone could secure your company a first‑mover advantage in the world’s largest patient market.
